Arthritis and bone loss: A hen and egg story

Current Opinion in Rheumatology

Volumn 26, Issue 1, 2014, Pages 80-84

  Kleyer, Arnd ^a   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

autoantibodies; bone erosion; rheumatoid arthritis; synovitis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTICITRULLINATED PROTEIN ANTIBODY; CATHESPIN K; COLLAGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FIBRINOGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN ANTIBODY; PROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIMENTIN;

AUTOIMMUNITY; BONE DESTRUCTION; BONE EROSION; BONE INJURY; CELL DIFFERENTIATION; CELL LINEAGE; CORTICAL BONE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; IMMUNE RESPONSE; MESENCHYME CELL; MONOCYTE; MONONUCLEAR CELL; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOGENESIS; POROSITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; TRABECULAR BONE;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BONE RESORPTION; CITRULLINE; HUMANS; OSTEOPOROSIS; PEPTIDES, CYCLIC; SYNOVITIS;

EID: 84890221698     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000007     Document Type: Review

References (34)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-2219.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423:356-361.
3. Schett G, Teitelbaum SL. Osteoclasts and arthritis. J Bone Miner Res 2009; 24:1142-1146.
4. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009; 5:667-676.
5. Geusens P. The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2012; 4:225-233.
6. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- And RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821-831.
7. Gerlag DM, Raza K, van Baarsen LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: Report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012; 71:638-641.
8. Pruijn GJ, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010; 12:203.
9. Whiting PF, Smidt N, Sterne JA, et al. Systematic review: Accuracy of anticitrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010; 152:456-464; W155-66.
10. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741-2749.
11. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205-1213.
12. Kallberg H, Padyukov L, Plenge RM, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80:867-875.
13. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38-46.
14. Wegner N, Wait R, Sroka A, et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: Implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010; 62: 2662-2672.
15. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anticyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43:1831-1835.
16. Ronnelid J, Wick MC, Lampa J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: Anti-CCP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005; 64:1744-1749.
17. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 2004; 50:709-715.
18. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: Association with HLA-DRB1, rheumatoid factor, and anticitrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008; 58:1293-1298.
19. Bukhari M, Thomson W, Naseem H, et al. The performance of anticyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis Rheum 2007; 56:2929-2935.
20. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62:120-126.
21. Quinn MA, Gough AK, Green MJ, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006; 45:478-480.
22. Syversen SW, Goll GL, van der Heijde D, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: Results from a 10-year prospective study. Ann Rheum Dis 2010; 69:345-351.
23. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005; 7:R949-R958.
24. Güler-Yüksel M, Klarenbeek NB, Goekoop-Ruiterman YP, et al. Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. Arthritis Res Ther 2010; 12:R96.
25. Kocijan R, Finzel S, Englbrecht M, et al. Differences in bone structure between rheumatoid arthritis and psoriatic arthritis patients depend on autoantibody positivity. Ann Rheum Dis 2013; doi 10.1136/annrheumdis-2013- 203791.
26. Guler H, Turhanoglu AD, Ozer B, et al. The relationship between anticyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis. Scand J Rheumatol 2008; 37:337-342.
27. Boyesen P, Hoff M, Odega° rd S, et al. Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: A longitudinal study. Arthritis Res Ther 2009; 11:R103.
28. Stach CM, Bäuerle M, Englbrecht M, et al. Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum 2010; 62:330-339.
29. Kleyer A, Finzel S, Rech J, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 2013. [Epub ahead of print]
30. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis: MRI bone oedema and anti- CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010; 69: 1789-1795.
31. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122:1791-1802. First data on how anticitrullinated protein antibodies trigger bone loss
32. van Schaardenburg D, Nielen MM, Lems WF, et al. Bone metabolism is altered in preclinical rheumatoid arthritis. Ann Rheum Dis 2011; 70:1173- 1174.
33. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008; 168:159-166.
34. Willis VC, Demoruelle MK, Derber LA, et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at-risk for future clinically apparent disease. Arthritis Rheum 2013; 65:2545-2554.